Prognostic value of systemic inflammation markers in early stage non-small cell lung cancer.

Creative Commons License

Akcam T. I., Tekneci A. K., Turhan K., Duman S., Cuhatutar S., Ozkan B., ...Daha Fazla

Scientific reports, cilt.15, sa.1, ss.33886, 2025 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1038/s41598-025-08683-y
  • Dergi Adı: Scientific reports
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Chemical Abstracts Core, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.33886
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

The present study investigates the prognostic significance of systemic inflammation markers in

patients with early-stage non-small cell lung cancer (NSCLC), who underwent surgical treatment.

We retrospectively analyzed data from 2,159 patients, who underwent lung resection for stage I-IIA

NSCLC in nine centers between the years 2010 and 2022. In order to compare survival, we grouped the

patients by preoperative neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR),

platelet-to-lymphocyte ratio (PLR), and pan-immune inflammation value (PIV). The mean overall

survival (OS) was significantly shorter in patients with high NLR (102.7 vs. 109.4 months, p = 0.040).

A low LMR was associated with worse OS (101 vs. 110.3 months, p < 0.001) and worse disease-free

survival (DFS) (100.2 vs. 108.6 months, p = 0.020). A high PLR was a poor prognostic factor for both

OS (104.1 vs. 110.1 months, p = 0.017) and DFS (102.5 vs. 108.7 months, p = 0.021). A high PIV was

associated with worse DFS (101.2 vs. 109.8 months, p = 0.003). Patients with high PIV had longer time

to chest tube removal (6.9 vs. 6.7 days, p = 0.049) and longer hospital stays (8.6 vs. 8.2 days, p < 0.001).

Complication rates were higher in patients with lower LMR (33.8% vs. 29.4%, p = 0.028) and higher

PLR (38.1% vs. 33.1%, p = 0.016). In our multicenter study, OS was worse in patients with high PLR,

high NLR, and low LMR. DFS was worse in patients with high PIV, high PLR, and low LMR. NLR, LMR,

PLR, and PIV were associated with OS and DFS in early-stage NSCLC, but none of the circulating

inflammatory markers proved to be statistically significant in the multivariate analysis.